INHALE-1:吸入式Technosphere胰岛素治疗儿童1型糖尿病的多中心随机试验
该多中心随机试验纳入230例4–17岁接受每日多次胰岛素注射的糖尿病患儿(1型98%、2型2%),按1:1随机分为吸入式Technosphere胰岛素(TI)组与速效类似物(RAA)胰岛素组,两组均继续基础胰岛素治疗并使用CGM,随访26周。主要终点HbA1c变化未达到预设的非劣效标准(校正差值0.18;95%CI -0.07, 0.43;非劣效P=0.091)。TI安全且不影响肺功能,治疗满意度更高、体重与BMI百分位增长更少。
要点
- HbA1c非劣效性未达到预设标准,TI组26周HbA1c较基线略升。
- 26周内TI安全性可接受,肺功能(FEV1)与RAA组无差异。
- TI组治疗满意度更高,体重与BMI百分位增长少于RAA组。
核心结论
- 主要分析未达到预设的HbA1c非劣效标准。
- TI使用26周安全且不影响肺功能,并与更高治疗满意度和更少体重增长相关,支持TI作为部分儿童1型糖尿病患者的治疗选择。
研究设计与样本
- 多中心随机对照试验,230例4–17岁糖尿病患儿(1型98%、2型2%)。
- 按1:1随机分为吸入式Technosphere胰岛素(TI)组与速效类似物(RAA)胰岛素组,两组均继续长效基础胰岛素并持续CGM,随访26周。
- 主要终点为HbA1c变化,非劣效界值0.4%。
主要发现
- TI组HbA1c由基线8.22±0.87%升至26周8.41±1.38%,RAA组由8.21±0.96%至8.21±1.10%(校正差值0.18;95%CI -0.07, 0.43;非劣效P=0.091)。
- CGM测得的70–180 mg/dL范围内时间两组无显著差异(校正差值-2.2%;95%CI -7.0, 2.7;P=0.38)。
- TI组发生2例严重低血糖事件,RAA组1例。
- 第1秒用力呼气容积从基线至26周的变化两组无差异(P=0.53)。
- TI组治疗满意度更高(P=0.004),体重与BMI百分位增长少于RAA组(P=0.009)。
关键数值与推荐
- 主要终点非劣效界值为0.4%。
- HbA1c校正差值0.18(95%CI -0.07, 0.43),非劣效P=0.091。
- CGM范围内时间校正差值-2.2%(95%CI -7.0, 2.7;P=0.38)。
临床怎么用
- TI可作为部分儿童1型糖尿病患者的治疗选择,但需权衡HbA1c非劣效未达标的结果。
- TI可能适合重视治疗满意度且关注体重增长的患者,使用中应监测血糖与肺功能。
局限性
- 主要分析未达到预设的HbA1c非劣效标准,提示TI在血糖控制方面不优于RAA。
- 研究对象以1型糖尿病为主(98%),2型糖尿病患儿仅占2%,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate inhaled technosphere insulin (TI) in children with diabetes. RESEARCH DESIGN AND METHODS: A total of 230 youth 4-17 years old with type 1 (98%) or type 2 (2%) diabetes treated with multiple daily injections of insulin were randomly assigned 1:1 to TI or rapid-acting analog (RAA) insulin plus continuation of long-acting basal insulin and continuous glucose monitoring (CGM) for 26 weeks. The primary outcome was change in HbA1c, tested for noninferiority with margin of 0.4%. RESULTS: In intent-to-treat analysis, mean HbA1c (% ± SD) was 8.22 ± 0.87 at baseline and 8.41 ± 1.38 at 26 weeks with TI and 8.21 ± 0.96 and 8.21 ± 1.10, respectively, with RAA (adjusted difference = 0.18; 95% CI -0.07, 0.43; noninferiority P = 0.091). CGM-measured time in range 70-180 mg/dL was not significantly different between groups (adjusted difference -2.2%; 95% CI -7.0, 2.7; P = 0.38). Two severe hypoglycemic events occurred in the TI group and one in the RAA group. Change in forced expiration volume in 1 s from baseline to 26 weeks did not differ comparing TI and RAA (P = 0.53). The TI group reported greater treatment satisfaction (P = 0.004) and had less gain in weight and BMI percentile (P = 0.009) than did the RAA group. CONCLUSIONS: The primary analysis did not meet the prespecified criteria for HbA1c noninferiority. However, TI use was safe over 26 weeks without affecting pulmonary function and was associated with greater treatment satisfaction and less weight gain compared with RAA, supporting TI as a treatment option for some pediatric patients with type 1 diabetes.
引用
- Haller MJ, Kanapka L, Monzavi R, et al. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes. Diabetes Care. 2026. PMID: 41223151. doi:10.2337/dc25-1994
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。